JPWO2019212899A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019212899A5 JPWO2019212899A5 JP2020560463A JP2020560463A JPWO2019212899A5 JP WO2019212899 A5 JPWO2019212899 A5 JP WO2019212899A5 JP 2020560463 A JP2020560463 A JP 2020560463A JP 2020560463 A JP2020560463 A JP 2020560463A JP WO2019212899 A5 JPWO2019212899 A5 JP WO2019212899A5
- Authority
- JP
- Japan
- Prior art keywords
- ligand
- inhibitor
- subject
- polymorphism
- nucleobase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010017987 CD30 Ligand Proteins 0.000 claims 25
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims 25
- 239000003112 inhibitor Substances 0.000 claims 23
- 238000000034 method Methods 0.000 claims 6
- 208000011231 Crohn disease Diseases 0.000 claims 5
- 108700028369 Alleles Proteins 0.000 claims 4
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims 4
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 101600095921 Homo sapiens Tumor necrosis factor ligand superfamily member 15 (isoform 1) Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 102300040494 Tumor necrosis factor ligand superfamily member 15 isoform 1 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 238000011272 standard treatment Methods 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024090213A JP7832987B2 (ja) | 2018-04-30 | 2024-06-03 | 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664720P | 2018-04-30 | 2018-04-30 | |
| US62/664,720 | 2018-04-30 | ||
| US201862681557P | 2018-06-06 | 2018-06-06 | |
| US62/681,557 | 2018-06-06 | ||
| US201862784179P | 2018-12-21 | 2018-12-21 | |
| US62/784,179 | 2018-12-21 | ||
| PCT/US2019/029402 WO2019212899A1 (en) | 2018-04-30 | 2019-04-26 | Methods and systems for selection and treatment of patients with inflammatory diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024090213A Division JP7832987B2 (ja) | 2018-04-30 | 2024-06-03 | 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532060A JP2021532060A (ja) | 2021-11-25 |
| JPWO2019212899A5 true JPWO2019212899A5 (https=) | 2022-05-09 |
| JP2021532060A5 JP2021532060A5 (https=) | 2022-05-09 |
Family
ID=68386125
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560463A Pending JP2021532060A (ja) | 2018-04-30 | 2019-04-26 | 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム |
| JP2024090213A Active JP7832987B2 (ja) | 2018-04-30 | 2024-06-03 | 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024090213A Active JP7832987B2 (ja) | 2018-04-30 | 2024-06-03 | 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12305236B2 (https=) |
| EP (2) | EP4296285A3 (https=) |
| JP (2) | JP2021532060A (https=) |
| KR (2) | KR20210013062A (https=) |
| CN (1) | CN112368301B (https=) |
| AU (1) | AU2019261933B2 (https=) |
| CA (1) | CA3098720A1 (https=) |
| DK (1) | DK3774897T5 (https=) |
| ES (1) | ES2962715T3 (https=) |
| FI (1) | FI3774897T3 (https=) |
| HR (1) | HRP20231367T1 (https=) |
| HU (1) | HUE063908T2 (https=) |
| LT (1) | LT3774897T (https=) |
| MA (1) | MA52251A (https=) |
| MD (1) | MD3774897T2 (https=) |
| PL (1) | PL3774897T3 (https=) |
| PT (1) | PT3774897T (https=) |
| RS (1) | RS64747B1 (https=) |
| SI (1) | SI3774897T1 (https=) |
| TW (1) | TW202003573A (https=) |
| WO (1) | WO2019212899A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014003689A (es) | 2011-09-30 | 2014-12-05 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos contra tl1a y sus usos. |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| ES2962715T3 (es) | 2018-04-30 | 2024-03-20 | Cedars Sinai Medical Center | Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias |
| WO2020112890A1 (en) | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Rnaset2 compositions and methods of treatment therewith |
| KR20210130168A (ko) * | 2019-02-08 | 2021-10-29 | 세다르스-신나이 메디칼 센터 | Il18r1을 표적화하는 염증성 질환의 치료를 위한 방법, 시스템 및 키트 |
| JP2022533956A (ja) | 2019-05-14 | 2022-07-27 | プロメテウス バイオサイエンシーズ，インク． | Ｔｌ１ａ患者を選択する方法、システム、およびデバイス |
| CA3197828A1 (en) * | 2020-11-13 | 2022-05-19 | Laurens Kruidenier | Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a |
| EP4256086A4 (en) * | 2020-12-01 | 2025-01-15 | Cedars-Sinai Medical Center | METHODS AND SYSTEMS FOR STRATIFICATION OF PATIENTS WITH INFLAMMATORY DISEASES |
| WO2022177963A1 (en) | 2021-02-17 | 2022-08-25 | Prometheus Biosciences, Inc. | Anti-cd30l antibodies and uses thereof |
| EP4562038A1 (en) * | 2022-07-27 | 2025-06-04 | Cephalon LLC | Anti-tl1a antibody formulations |
| CA3262839A1 (en) * | 2022-07-27 | 2024-02-01 | Cephalon Llc | ANTI-TL1A ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE |
| WO2024143497A1 (ja) * | 2022-12-28 | 2024-07-04 | 国立大学法人京都大学 | Ｃｄ１５３を標的とする医薬組成物 |
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US5011692A (en) | 1985-12-28 | 1991-04-30 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| DE69334070T2 (de) | 1992-05-26 | 2007-01-04 | Immunex Corp., Thousand Oaks | Neue zytokine die cd30 binden |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| US6652854B2 (en) | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| US6960563B2 (en) | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
| US20060194265A1 (en) | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
| US20080233119A2 (en) | 2003-08-20 | 2008-09-25 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
| WO2008106451A2 (en) * | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| AU2010244640A1 (en) * | 2009-03-27 | 2011-08-11 | Merck Serono S.A. | Genetic severity markers in Multiple Sclerosis |
| US8486939B2 (en) | 2009-07-07 | 2013-07-16 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| WO2011020906A2 (en) * | 2009-08-21 | 2011-02-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | sPLA2 IIA POLYMORPHISM ANALYSIS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT |
| JP6124800B2 (ja) | 2011-11-30 | 2017-05-10 | 中外製薬株式会社 | 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬 |
| CN117264057A (zh) * | 2012-04-27 | 2023-12-22 | 诺和诺德股份有限公司 | 人cd30配体抗原结合蛋白 |
| AU2013271336B2 (en) | 2012-06-04 | 2017-11-30 | Centre For Digestive Diseases | Compositions and methods for treating Crohn's Disease and related conditions and infections |
| EP3389781B1 (en) | 2015-12-15 | 2021-08-11 | University of Miami | Inhibitors of tnf superfamily costimulatory interactions and methods for uses of the same |
| MY191324A (en) * | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| ES2962715T3 (es) | 2018-04-30 | 2024-03-20 | Cedars Sinai Medical Center | Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias |
-
2019
- 2019-04-26 ES ES19796203T patent/ES2962715T3/es active Active
- 2019-04-26 CA CA3098720A patent/CA3098720A1/en active Pending
- 2019-04-26 RS RS20231000A patent/RS64747B1/sr unknown
- 2019-04-26 EP EP23192639.5A patent/EP4296285A3/en active Pending
- 2019-04-26 JP JP2020560463A patent/JP2021532060A/ja active Pending
- 2019-04-26 HU HUE19796203A patent/HUE063908T2/hu unknown
- 2019-04-26 FI FIEP19796203.8T patent/FI3774897T3/fi active
- 2019-04-26 SI SI201930656T patent/SI3774897T1/sl unknown
- 2019-04-26 EP EP19796203.8A patent/EP3774897B1/en active Active
- 2019-04-26 WO PCT/US2019/029402 patent/WO2019212899A1/en not_active Ceased
- 2019-04-26 AU AU2019261933A patent/AU2019261933B2/en active Active
- 2019-04-26 DK DK19796203.8T patent/DK3774897T5/da active
- 2019-04-26 MA MA052251A patent/MA52251A/fr unknown
- 2019-04-26 MD MDE20210158T patent/MD3774897T2/ro unknown
- 2019-04-26 KR KR1020207033851A patent/KR20210013062A/ko not_active Ceased
- 2019-04-26 CN CN201980044299.1A patent/CN112368301B/zh active Active
- 2019-04-26 LT LTEPPCT/US2019/029402T patent/LT3774897T/lt unknown
- 2019-04-26 US US17/051,731 patent/US12305236B2/en active Active
- 2019-04-26 PL PL19796203.8T patent/PL3774897T3/pl unknown
- 2019-04-26 KR KR1020257023772A patent/KR20250111409A/ko active Pending
- 2019-04-26 HR HRP20231367TT patent/HRP20231367T1/hr unknown
- 2019-04-26 PT PT197962038T patent/PT3774897T/pt unknown
- 2019-04-30 TW TW108115107A patent/TW202003573A/zh unknown
-
2024
- 2024-06-03 JP JP2024090213A patent/JP7832987B2/ja active Active
-
2025
- 2025-02-12 US US19/051,782 patent/US20250290143A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532060A5 (https=) | ||
| FI3774897T3 (fi) | Menetelmiä ja järjestelmiä tulehdustautisten potilaiden valintaan ja hoitoon | |
| Taki et al. | The t (11; 16)(q23; p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene | |
| JPWO2019212899A5 (https=) | ||
| Bogaert et al. | Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease | |
| KR101566064B1 (ko) | 연령-관련 황반 변성에서의 유전자 다형성 | |
| CA2544708A1 (en) | Liver cancer biomarkers | |
| MX2011004763A (es) | Polimorfismos geneticos en la degeneracion macular relacionada con la edad. | |
| EP3218515A1 (en) | Therapeutic and diagnostic methods for il-33-mediated disorders | |
| JP2010522555A (ja) | 乳癌のリスクアセスメント、診断、予後診断および治療における使用のためのマーカーとしてのｃｈｒ２およびｃｈｒ１６の遺伝的変異 | |
| HK1213295A1 (zh) | Vegf多态性和抗血管发生疗法 | |
| JP2009539960A (ja) | 加齢黄斑変性に対する保護および処置 | |
| EP3207136A1 (en) | Methods and compositions for treating a subject with a smad7 antisense oligonucleotide | |
| Han et al. | CCR5 gene polymorphism is a genetic risk factor for radiographic severity of rheumatoid arthritis | |
| Kresse et al. | Mapping and characterization of the amplicon near APOA2 in 1q23 in human sarcomas by FISH and array CGH | |
| Pauciullo et al. | Wingless‐type MMTV integration site family member 2 (WNT 2) gene is associated with resistance to MAP in faecal culture and antibody response in Holstein cattle | |
| KR20180109811A (ko) | 항암 치료 내성 판단 방법 및 상기 방법에 사용되는 조성물 | |
| Frenzel et al. | Sustained NF‐kappaB activity in chronic lymphocytic leukemia is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locus | |
| JP2021502977A5 (https=) | ||
| WO2015149720A1 (en) | Hnf4g-rspo2 fusion gene and use thereof in treatment of cancer | |
| KR101895853B1 (ko) | 마이크로 알엔에이(rna) 다형의 한국인 허혈성 뇌졸중(뇌경색) 발병 위험도 연관성 | |
| CA2896070A1 (en) | Biomarkers for chronic traumatic encephalopathy | |
| US7754422B2 (en) | Method of judging inflammatory disease | |
| Sainio et al. | Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus | |
| JP6348699B2 (ja) | インターフェロン治療効果予測方法 |